BAYER AG S/ADR (BAYRY) news covers developments at Bayer AG, a global life science enterprise active in health care and nutrition. Company communications highlight updates across its Pharmaceuticals Division, radiology business and crop science activities, giving investors and observers insight into how Bayer advances its pipeline and product portfolio.
Recent pharmaceutical news emphasizes growth in oncology, cardiology, neurology, immunology and women’s health. Examples include updates on asundexian for secondary stroke prevention, finerenone (Kerendia) in cardiovascular-kidney-metabolic conditions, and oncology assets such as Nubeqa for prostate cancer, Hyrnuo for HER2-mutant non-small cell lung cancer, and Xofigo for metastatic castration-resistant prostate cancer with bone metastases. Bayer also reports on Lynkuet, a hormone-free treatment for moderate to severe hot flashes due to menopause, and a Phase III SUNFLOWER study evaluating Mirena for nonatypical endometrial hyperplasia.
News items also describe Bayer’s work in radiology and molecular imaging, including the low-dose MRI contrast agent gadoquatrane and the acquisition of investigational tracers AT-01 and AT-05 for diagnosing cardiac amyloidosis. Additional coverage highlights cell and gene therapy programs for Parkinson’s disease and ophthalmic conditions, as well as collaborations such as the agreement with Soufflé Therapeutics to develop a heart-targeted siRNA therapy for a form of dilated cardiomyopathy.
On the agriculture side, Bayer Crop Science Canada announcements feature launches like Sivanto Energy for flea beetle control in canola and EverGol Rise for pulse disease control. Together, these updates illustrate how Bayer seeks to execute its mission “Health for all, Hunger for none” through pharmaceutical innovation, diagnostic imaging advances and crop protection solutions.
Bayer (OTC:BAYRY) outlined an accelerated Pharmaceuticals growth strategy at the J.P. Morgan Healthcare Conference focusing on oncology, cardiology, neurology, immunology, women’s health, and molecular imaging.
Key facts: five pivotal approvals in 2025; Phase III OCEANIC-STROKE met primary endpoints for asundexian; finerenone (Kerendia) approved in US and Japan for HF with LVEF ≥40% with other markets under review; Nubeqa has treated over 200,000 patients; FDA granted accelerated approval to Hyrnuo (sevabertinib). Bayer launched CGT, gene therapy and imaging programs and acquired two investigational radiotracers to enter molecular imaging.
Bayer (OTC: BAYRY) partnered with actress Gabrielle Union-Wade on the “Life Doesn’t Stop for a Hot Flash” campaign to raise awareness of treatment options for moderate to severe hot flashes due to menopause. The campaign highlights Lynkuet (elinzanetant) 60 mg, a hormone-free, FDA-approved prescription treatment for moderate to severe hot flashes, approved in October 2025, and will run across digital channels and streaming services encouraging conversations with healthcare providers. Safety information and prescribing guidance, including liver monitoring and pregnancy warnings, are included.
Bayer (OTC:BAYRY) agreed to acquire two investigational molecular imaging tracers from Attralus: AT-01 (124-iodine evuzamitide) and AT-05 (PAR-peptide + technetium-99m). AT-01 is in Phase III and holds FDA Breakthrough Therapy plus Orphan Drug designations (U.S. and EU); AT-05 is in Phase I. The acquisition expands Bayer into diagnostic tracers for cardiac and systemic amyloidosis, a disease estimated to affect ~400,000 people globally, and complements Bayer’s radiology and cardiovascular portfolio. Financial terms were not disclosed. Attralus will refocus on its therapeutic programs including AT-02 in Phase II.
Bayer (OTC: BAYRY) and Soufflé Therapeutics announced a strategic collaboration and global license to develop a cell-selective, heart-targeted siRNA therapy for a form of dilated cardiomyopathy affecting a rare subset of patients. The partnership combines Soufflé’s proprietary ligand and siRNA engineering to deliver therapies directly to cardiomyocytes with Bayer’s cardiovascular development expertise. The program aims to reduce off-target effects and dosing frequency by improving targeted delivery to heart muscle cells. Financial terms and clinical timelines were not disclosed.
Bayer (OTC:BAYRY) will present at the 44th J.P. Morgan Healthcare Conference in San Francisco, held January 12–15, 2026.
Stefan Oelrich, Member of the Board of Management and President of Bayer’s Pharmaceuticals Division, will deliver an update on Bayer’s pharmaceutical growth strategy and pipeline advancements on Tuesday, January 13, 2026, 11:15–11:55 PST. The presentation will be available via live webcast and later posted with related materials on Bayer's website.
Bayer Crop Science (BAYRY) launched Sivanto Energy on December 16, 2025, a foliar insecticide for canola targeting flea beetles.
The product combines two active ingredients — deltamethrin (Group 3) and flupyradifurone (Group 4D) — to offer dual modes of action, rapid knockdown and systemic protection for up to 4 days. Bayer positions the formulation as delivering extended residual control and flexibility for growers managing flea beetle pressure.
Bayer (OTC:BAYRY) announced initiation of the ASSESS Phase IIa randomized, double-blind, placebo-controlled study (NCT07211685) of BAY 3401016, an investigational monoclonal antibody that may block Semaphorin 3A (Sema3A) to address kidney damage in Alport Syndrome (AS).
The first-in-patient adult trial includes an extension phase and follows Bayer’s research collaboration with Evotec. The program has received Fast Track and Orphan Drug designations from the U.S. FDA. The study aims to evaluate the efficacy and safety of BAY 3401016 in slowing loss of kidney function in adults with rapidly progressing AS.
Bayer (OTC:BAYRY) announced that the QUANTI Pediatric study of investigational MRI contrast agent gadoquatrane met primary and secondary endpoints when used at 0.04 mmol Gd/kg—a 60% dose reduction versus macrocyclic GBCAs dosed at 0.1 mmol Gd/kg. The study showed similar pharmacokinetic behavior in children (birth to <18) as in adults. Results were presented at RSNA (Nov 30–Dec 4, 2025).
Based on positive QUANTI data, Bayer has submitted marketing authorization applications for gadoquatrane in multiple markets, including Japan, the U.S., the EU, and China. If approved, gadoquatrane would be the lowest-dose macrocyclic GBCA in those markets.
Bayer (OTC:BAYRY) announced the start of SUNFLOWER, a Phase III investigational study testing the 52 mg levonorgestrel-releasing intrauterine system Mirena for treatment of nonatypical endometrial hyperplasia (NAEH).
The randomized study will compare Mirena versus an oral progestin, plans to enroll 207 patients across about 90 centers in three countries, and is expected to complete after roughly 18 months. Mirena is globally available in more than 120 countries and is approved in the U.S. for contraception (up to 8 years) and for heavy menstrual bleeding (up to 5 years) but is not FDA approved for NAEH. The company cites a high unmet need, noting approximately 121 per 100,000 women develop NAEH each year and current absence of approved U.S. medical therapies.
Bayer Crop Science (OTC:BAYRY) launched EverGol Rise in Canada, a single‑formulation pulse seed treatment combining four active ingredients to expand control to seed‑ and soil‑borne pathogens including ascochyta.
The product is premeasured at 100 ml/100 kg, requires no mixing, offers deeper pigment for visual coverage, and will be sold in 9 L jugs and 27 L drums. Bayer completed over 90 pre‑commercial trials across Western Canada and plans commercial availability for the 2026 growing season.